SCHEMBL20164663

SCHEMBL20164663

CCNc1nc(NCC)c2nc(NC[C@H](C)O)nc(NCC)c2n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 5/20 0.42
CCNE1 P24864 3/20 0.42
CDK1 P06493 3/20 0.41
SLC29A1 Q99808 1/20 0.41
CDK9 P50750 2/20 0.38
CDK7 P50613 1/20 0.38
CDK5 Q00535 1/20 0.38
FLT3 P36888 1/20 0.38
LMNA P02545 1/20 0.37
GAA P10253 2/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20164392 1.00 CDK2 (0.42) CDK2CCNE1CDK1SLC29A1CDK9
SCHEMBL20164389 1.00 CDK2 (0.42) CDK2CCNE1CDK1SLC29A1CDK9
Hydrochloric Acid SCHEMBL20164619 0.98 CDK2 (0.41) CDK2CCNE1CDK1SLC29A1CDK9
Hydrochloric Acid SCHEMBL20164441 0.98 CDK2 (0.41) CDK2CCNE1CDK1SLC29A1CDK9
Hydrochloric Acid SCHEMBL20164438 0.98 CDK2 (0.41) CDK2CCNE1CDK1SLC29A1CDK9
SCHEMBL20164374 0.91 SLC29A1 (0.48) CDK2CCNE1CDK1SLC29A1CDK9
SCHEMBL20164373 0.91 SLC29A1 (0.48) CDK2CCNE1CDK1SLC29A1CDK9
SCHEMBL20164535 0.91 SLC29A1 (0.48) CDK2CCNE1CDK1SLC29A1CDK9
SCHEMBL20164393 0.89 CDK2 (0.43) CDK2CCNE1CDK1SLC29A1CDK9
Hydrochloric Acid SCHEMBL20164507 0.89 SLC29A1 (0.47) CDK2CCNE1CDK1SLC29A1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US claimed
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed
CN-107708701-A Novel respiratory control modulating compounds and methods of making and using the same 纽拉德有限公司 2018-02-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 CDK2 4026/4885CCNE1 4167/4885CDK1 3077/4885
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF GPR119, GPR35, GPR55 CDK2 3942/4885CCNE1 2993/4885CDK1 3085/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 CDK2 4190/4885CCNE1 4321/4885CDK1 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.